2 unknown, 1 completed, 1 not yet recruiting, 1 recruiting. 3 Phase 1, 2 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Completed 1, Recruiting 1, Unknown 1 |
| Phase 2 | 2 | Not yet recruiting 1, Unknown 1 |
| Phase 3 | 1 | Unknown 1 |
Follow ASK120067: new trials by email Literature Review of ASK120067 trials Research Report on ASK120067
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Clinical Study on the Efficacy and Safety of the Combination of Limertinib and Bevacizumab Versus Limertinib as First-line Treatment for NSCLC. Limertinib+bevacizumab, Limertinib - EGFR Mutation Positive Advanced Non Small Cell Lung Cancer, PD-L1 Positive | Phase 2 | Not yet recruiting | Shanghai Chest Hospital | 136 | 2025-06-30 | 2025-05-21 |
| Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumor Activity of ASKC202 With or Without ASK120067 ASKC202, ASK120067 - Advanced Solid Tumor | Phase 1 | Recruiting | Jiangsu Aosaikang Pharmaceutical Co., Ltd. | 150 | 2022-08-08 | 2025-12-23 |
| Assessing the Pharmacokinetics Effects of Food on ASK120067 in Single Oral Administration in Chinese Healthy Subjects ASK120067, ASK120067 in fed condition - Locally Advanced or Metastatic NSCLC | Phase 1 | Completed | Jiangsu Aosaikang Pharmaceutical Co., Ltd. | 24 | 2019-12-09 | 2020-04-29 |
| ASK120067 Versus Gefitinib as First-line Treatment for EGFRm Locally Advanced or Metastatic NSCLC ASK120067, Placebo Gefitinib 250 mg, Gefitinib - Locally Advanced or Metastatic NSCLC | Phase 3 | Unknown | Jiangsu Aosaikang Pharmaceutical Co., Ltd. | 337 | 2019-07-23 | 2024-06-14 |
| Safety, Tolerability, Pharmacokinetics and Anti-tumour Activity of ASK120067 in Locally Advanced and Metastatic Non Small Cell Lung Cancer ASK120067 - Locally Advanced or Metastatic NSCLC | Phase 1 / Phase 2 | Unknown | Jiangsu Aosaikang Pharmaceutical Co., Ltd. | 507 | 2017-11-30 | 2020-09-16 |
Carcinoma, Non-Small-Cell Lung (3)
Jiangsu Aosaikang Pharmaceutical Co., Ltd. (4) · Shanghai Chest Hospital (1)
China (4)
Zhou Caicun, MD (1) · Zourong Ruan (1)